ba37d677-fb91-4aab-80a9-b2fd0bc39057
—
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- —
- age_years
- 71.7481177275838
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- E2F_TARGETS+0.550
- G2M_CHECKPOINT+0.520
- MYC_TARGETS_V2+0.470
- MYC_TARGETS_V1+0.380
- WNT_BETA_CATENIN_SIGNALING+0.360
- SPERMATOGENESIS+0.250
- MTORC1_SIGNALING+0.200
- DNA_REPAIR+0.150
- ANGIOGENESIS+0.110
- UNFOLDED_PROTEIN_RESPONSE+0.070
Top 10 suppressed
- REACTIVE_OXYGEN_SPECIES_PATHWAY-0.360
- TNFA_SIGNALING_VIA_NFKB-0.320
- P53_PATHWAY-0.310
- PANCREAS_BETA_CELLS-0.290
- IL6_JAK_STAT3_SIGNALING-0.280
- OXIDATIVE_PHOSPHORYLATION-0.280
- PROTEIN_SECRETION-0.270
- APICAL_JUNCTION-0.240
- HYPOXIA-0.220
- INFLAMMATORY_RESPONSE-0.220
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
4 twins match this tumor's tissue · 6 come from a different tissue of origin ← cross-tissue dominant
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | ERR2598228 | fetal | fetal | 0.796 |
| 2 | SRR10900597 | — | — | 0.789 |
| 3 | 12256b85-6662-41b3-a5d4-890ced0222e5 | — | — | 0.786 |
| 4 | BS_S71RJ8DH | ATRT | — | 0.783 |
| 5 | s0095110 | — | — | 0.780 |
| 6 | cfda240e-d071-418b-9a7d-a6fd30e60cdf | — | — | 0.778 |
| 7 | MDT-AP-3200 | Med | Medulloblastoma | 0.778 |
| 8 | BS_K25F4J3V | ATRT | — | 0.776 |
| 9 | BS_V72H4RQS | medulloblastoma | — | 0.774 |
| 10 | SJEPD036_D.RNA-Seq | EPN | Supratentorial EPN | 0.773 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 16 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| E2F_TARGETS | 0.550 | Inavolisib | — uncovered |
| G2M_CHECKPOINT | 0.520 | Inavolisib | — uncovered |
| MYC_TARGETS_V2 | 0.470 | Idelalisib | — uncovered |
| MYC_TARGETS_V1 | 0.380 | Inavolisib | — uncovered |
| WNT_BETA_CATENIN_SIGNALING | 0.360 | Inavolisib | — uncovered |
| SPERMATOGENESIS | 0.250 | Inavolisib | — uncovered |
| MTORC1_SIGNALING | 0.200 | Inavolisib | — uncovered |
| DNA_REPAIR | 0.150 | Idelalisib | — uncovered |
| ANGIOGENESIS | 0.110 | Remibrutinib | — uncovered |
| UNFOLDED_PROTEIN_RESPONSE | 0.070 | Idelalisib | — uncovered |
| UV_RESPONSE_DN | 0.070 | Inavolisib | — uncovered |
| KRAS_SIGNALING_DN | 0.040 | Remibrutinib | — uncovered |
| PEROXISOME | 0.030 | Idelalisib | — uncovered |
| CHOLESTEROL_HOMEOSTASIS | 0.020 | Remibrutinib | — uncovered |
| HEME_METABOLISM | 0.020 | Temsirolimus | — uncovered |
| UV_RESPONSE_UP | 0.010 | Idelalisib | — uncovered |